SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$25.55

02 Jul
2024

-0.110

OPEN

$25.45

-0.43%

HIGH

$25.68

1,038,119

LOW

$25.38

TARGET
$29.832 16.8% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 145.8 104.9 xxx
DPS (cps) xxx 104.0 92.6 xxx
EPS Growth xxx - 52.3% - 28.0% xxx
DPS Growth xxx 4.0% - 11.0% xxx
PE Ratio xxx N/A 24.5 xxx
Dividend Yield xxx N/A 3.6% xxx
Div Pay Ratio(%) xxx 71.3% 88.2% xxx

Dividend yield today if purchased 3 years ago: 2.73%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 4.05

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/03 - ex-div 43c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic 112.6122.5111.1275.5305.5145.8
DPS All 81.084.085.091.0100.0104.0
Sales/Revenue 5,419.7 M5,870.9 M6,562.6 M9,127.8 M9,306.5 M7,964.9 M
Book Value Per Share 983.71,142.01,173.01,336.01,542.11,643.2
Net Operating Cash Flow 767.9 M847.3 M1,360.3 M2,042.8 M2,225.8 M1,471.0 M
Net Profit Margin 8.78 %9.36 %8.04 %14.41 %15.69 %8.60 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed 11.88 %11.46 %9.61 %21.99 %21.39 %9.13 %
Return on Invested Capital 7.40 %7.53 %6.16 %14.14 %15.36 %6.70 %
Return on Assets 5.81 %5.94 %4.64 %10.56 %11.51 %5.14 %
Return on Equity 11.88 %11.46 %9.61 %21.99 %21.39 %9.13 %
Return on Total Capital 8.31 %6.45 %5.75 %22.87 %21.20 %7.64 %
Free Cash Flow ex dividends 308.6 M200.6 M721.7 M1,353.7 M1,483.5 M601.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt 4 M826 M663 M551 M342 M347 M
Long Term Debt 2,792 M2,210 M3,953 M2,683 M2,671 M2,754 M
Total Debt 2,796 M3,036 M4,616 M3,235 M3,013 M3,100 M
Goodwill - Gross 5,338 M6,423 M6,586 M6,331 M6,949 M7,336 M
Cash & Equivalents - Generic 313 M737 M1,230 M900 M780 M798 M
Price To Book Value 2.492.372.592.872.142.16

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex 327.6 M386.6 M333.1 M363.2 M378.6 M497.0 M
Capex % of Sales 6.05 %6.59 %5.08 %3.98 %4.07 %6.24 %
Cost of Goods Sold 3,718 M4,117 M4,897 M5,616 M5,894 M5,851 M
Selling, General & Admin. Exp & Other 1,125 M1,251 M1,125 M1,223 M1,273 M1,294 M
Research & Development ------
Investments - Total 40 M88 M92 M108 M145 M176 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

22/05/2024

1

Add

$31.19

22.07%

Ongoing inflationary pressure and currency headwinds have conspired to lower Sonic Healthcare's earnings, observes Morgans.

Management noted these hurdles are “delaying the completion of programs to align labour costs with current trading conditions”.

As a result of these headwinds, FY24 earnings guidance is lowered to around $1.6bn from the lower end of the $1.7-1.8bn range.

The broker suggests preliminary FY25 earnings guidance of between $1.7-1.75bn is conservative, given evidence of waning inflation, ongoing cost-out and multiple earnings drivers.

The Add rating is maintained, but the target is reduced to $31.19 from $34.94 on the broker's lower FY24-26 forecasts.

FORECAST
Morgans forecasts a full year FY24 dividend of 91.00 cents and EPS of 103.00 cents.
Morgans forecasts a full year FY25 dividend of 95.00 cents and EPS of 125.00 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

SHL STOCK CHART

FNArena News on SHL

1
June In Review: FY24 Another Double Digit Return

2:50 PM - Australia
2
Rudi’s View: Diverging Risks In A Polarised Market

10:00 AM - Rudi's View
3
Rudi’s View: Copper, Lithium, Retailers & TechnologyOne

Jun 27 2024 - Rudi's View
4
Rudi’s View: GenAi, The Super-Megatrend, Part 2

Jun 20 2024 - Rudi's View
5
Australian Broker Call *Extra* Edition – May 28, 2024

May 28 2024 - Daily Market Reports

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia